Radiopharm Theranostics (ASX:RAD) secured approval from the Data and Safety Monitoring Committee (DSMC) to proceed to the next dose in its first phase clinical trial for radiotherapeutic asset 177Lu-RAD204 in patients with PD-L1 positive advanced cancers, according to a Tuesday filing with the Australian bourse.
The DSMC confirmed the safety, pharmacokinetic, and biodistribution data of the first group of four patients treated with 30 millicurie of 177Lu-RAD204, allowing the study to continue without modifications, the filing said.
The second group will start at 60 millicurie of Lu177, expected to enroll by the middle of the year, and expand to multiple tumor types, according to the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.